Last reviewed · How we verify
NCT03177057: SMART
SMART Project in Preventing Skin Cancer
NA trial testing Compliance Monitoring in Skin Carcinoma in 114 participants. Completed in 31 December 2014.
30 July 2014
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 114 |
| Start date | 23 April 2013 |
| Primary completion | 30 July 2014 |
| Estimated completion | 31 December 2014 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Compliance Monitoring
- Health Telemonitoring
- Questionnaire Administration
Conditions studied
- Skin Carcinoma — all drugs for Skin Carcinoma →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
Adults 18 to 29, female only, with Skin Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot clinical trial studies how well Self Monitoring And Readiness Texting (SMART) project works in sun exposure and protection behaviors. Measuring how behavior tracking and individually tailored messages affect risk behaviors in patients with skin cancer may help doctors plan the best prevention plan and decrease national melanoma incidence and mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03177057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Compliance Monitoring
Trials testing the same drug.
- NCT06639958 — A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home · NA · suspended
- NCT00719303 — Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treat · Phase 3 · unknown
- NCT01503632 — Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remiss · Phase 3 · completed
- NCT00268528 — Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia i · completed
Other recruiting trials for Skin Carcinoma
Currently open trials in the same condition.
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT04358276 — Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Provide · NA · active not recruiting
- NCT04475640 — Cancer Genetic Testing in Ethnic Populations · NA · recruiting
- NCT02465060 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or M · Phase 2 · active not recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03177057 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 1 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03177057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing